[go: up one dir, main page]

ES2197003B1 - Nuevos compuestos antagonistas de integrinas alfa. - Google Patents

Nuevos compuestos antagonistas de integrinas alfa.

Info

Publication number
ES2197003B1
ES2197003B1 ES200200805A ES200200805A ES2197003B1 ES 2197003 B1 ES2197003 B1 ES 2197003B1 ES 200200805 A ES200200805 A ES 200200805A ES 200200805 A ES200200805 A ES 200200805A ES 2197003 B1 ES2197003 B1 ES 2197003B1
Authority
ES
Spain
Prior art keywords
integrinas
alfa
antagonist compounds
new
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200200805A
Other languages
English (en)
Other versions
ES2197003A1 (es
Inventor
Elena Carceller Gonzalez
Jorge Salas Solana
Cristina Alvarez Farrerons
Juan Andres Andreu Aranza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noucor Health SA
Original Assignee
J Uriach y Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200200805A priority Critical patent/ES2197003B1/es
Application filed by J Uriach y Cia SA filed Critical J Uriach y Cia SA
Priority to KR10-2004-7015916A priority patent/KR20040094912A/ko
Priority to EP03727281A priority patent/EP1495044A1/en
Priority to US10/510,626 priority patent/US20050143391A1/en
Priority to ARP030101227A priority patent/AR039401A1/es
Priority to AU2003233958A priority patent/AU2003233958A1/en
Priority to BR0309120-1A priority patent/BR0309120A/pt
Priority to CA002477943A priority patent/CA2477943A1/en
Priority to PCT/EP2003/003635 priority patent/WO2003084984A1/en
Priority to MXPA04008990A priority patent/MXPA04008990A/es
Priority to JP2003582179A priority patent/JP2006506320A/ja
Publication of ES2197003A1 publication Critical patent/ES2197003A1/es
Priority to NO20044330A priority patent/NO20044330L/no
Application granted granted Critical
Publication of ES2197003B1 publication Critical patent/ES2197003B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)

Abstract

Nuevos compuestos antagonistas de integrinas alfa. La presente invención se refiere a nuevos compuestos de fórmula I y sus sales, solvatos y prodrogas, en donde los significados de los distintos sustituyentes son como se indican en la parte descriptiva. Estos compuestos son útiles como antagonistas de integrinas alfa.
ES200200805A 2002-04-08 2002-04-08 Nuevos compuestos antagonistas de integrinas alfa. Expired - Fee Related ES2197003B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES200200805A ES2197003B1 (es) 2002-04-08 2002-04-08 Nuevos compuestos antagonistas de integrinas alfa.
PCT/EP2003/003635 WO2003084984A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
US10/510,626 US20050143391A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
ARP030101227A AR039401A1 (es) 2002-04-08 2003-04-08 Un compuesto antagonista de integrinas alfa 4 y un procedimiento para preparar el mismo
AU2003233958A AU2003233958A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
BR0309120-1A BR0309120A (pt) 2002-04-08 2003-04-08 Compostos com atividade antagonista de integrina alfa4
KR10-2004-7015916A KR20040094912A (ko) 2002-04-08 2003-04-08 알파-4 인테그린 안타고니스트 활성을 갖는 헤테로시클릭아미드
EP03727281A EP1495044A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
MXPA04008990A MXPA04008990A (es) 2002-04-08 2003-04-08 Amidas heterociclicas con actividad antagonista de (4 integrinas.
JP2003582179A JP2006506320A (ja) 2002-04-08 2003-04-08 α４インテグリン拮抗薬活性を有する新規化合物
CA002477943A CA2477943A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
NO20044330A NO20044330L (no) 2002-04-08 2004-10-12 Heterosykliske amider med alfa-4 intergrin-antagonistaktivitet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200805A ES2197003B1 (es) 2002-04-08 2002-04-08 Nuevos compuestos antagonistas de integrinas alfa.

Publications (2)

Publication Number Publication Date
ES2197003A1 ES2197003A1 (es) 2003-12-16
ES2197003B1 true ES2197003B1 (es) 2005-03-16

Family

ID=28686084

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200200805A Expired - Fee Related ES2197003B1 (es) 2002-04-08 2002-04-08 Nuevos compuestos antagonistas de integrinas alfa.

Country Status (12)

Country Link
US (1) US20050143391A1 (es)
EP (1) EP1495044A1 (es)
JP (1) JP2006506320A (es)
KR (1) KR20040094912A (es)
AR (1) AR039401A1 (es)
AU (1) AU2003233958A1 (es)
BR (1) BR0309120A (es)
CA (1) CA2477943A1 (es)
ES (1) ES2197003B1 (es)
MX (1) MXPA04008990A (es)
NO (1) NO20044330L (es)
WO (1) WO2003084984A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR050425A1 (es) * 2004-07-08 2006-10-25 Elan Pharm Inc Antagonistas multivalentes de vla-4 que comprende fracciones polimericas. composiciones farmaceuticas
MX2007007553A (es) * 2004-12-24 2007-08-15 Prosidion Ltd Agonistas del receptor acoplado a proteina g (gpr116) y uso de los mismos para tratar obesidad y diabetes.
US8030328B2 (en) 2005-05-20 2011-10-04 Elan Pharmaceuticals, Inc. Imidazolone phenylalanine derivatives
US8258159B2 (en) * 2005-06-07 2012-09-04 The Trustees Of The University Of Pennsylvania Inhibitors of the α2β1/GPIa-IIa integrin
US8987306B2 (en) 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
US20090203676A1 (en) * 2005-06-30 2009-08-13 Oscar Barba G-protein Coupled Receptor Agonists
TW200808723A (en) * 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
BRPI0819989A2 (pt) * 2007-12-05 2015-05-12 Biovitrum Ab Publ Composto, formulação farmacêutica, uso de um composto, processo para a preparação de um composto, e, métodos para tratamento ou prevenção de condições ou doênças e para inibição da angiogênese
KR20100097701A (ko) * 2007-12-05 2010-09-03 아스트라제네카 아베 비만 치료제로서의 모르폴린 유도체
KR20100096222A (ko) * 2007-12-05 2010-09-01 아스트라제네카 아베 피페라진 유도체 및 렙틴 수용체 조절물질로서 그 유도체의 용도
CA2720164A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
EP2459594A1 (en) 2009-07-31 2012-06-06 N.V. Organon Fully human antibodies to btla
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
EP3436046A4 (en) * 2016-04-01 2020-03-11 The Regents of The University of California INTEGRIN ALPHA 5 BETA 1 INHIBITORS AND METHODS OF USE
WO2018085552A1 (en) * 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists
WO2022049134A1 (en) * 2020-09-03 2022-03-10 F. Hoffmann-La Roche Ag Heterocyclic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2291778A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
CN1265670A (zh) * 1997-07-31 2000-09-06 伊兰药品公司 抑制vla－4介导的白细胞粘附的二肽和相关的化合物
KR100720907B1 (ko) * 1999-08-13 2007-05-25 바이오겐 아이덱 엠에이 인코포레이티드 세포 유착 억제제
EP1253923A1 (en) * 2000-01-28 2002-11-06 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses

Also Published As

Publication number Publication date
EP1495044A1 (en) 2005-01-12
MXPA04008990A (es) 2005-06-20
ES2197003A1 (es) 2003-12-16
JP2006506320A (ja) 2006-02-23
NO20044330L (no) 2004-10-28
KR20040094912A (ko) 2004-11-10
AU2003233958A1 (en) 2003-10-20
WO2003084984A1 (en) 2003-10-16
WO2003084984A8 (en) 2003-12-11
AR039401A1 (es) 2005-02-16
US20050143391A1 (en) 2005-06-30
BR0309120A (pt) 2005-01-11
CA2477943A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
ES2197003B1 (es) Nuevos compuestos antagonistas de integrinas alfa.
ECSP12006041A (es) Derivados de pirazolopiridina
ES2308299T3 (es) Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
ATE372768T1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste
MX9605128A (es) Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
CY1110392T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
CY1114008T1 (el) Θειενοπυριμιδινικες ενωσεις και χρηση τους
CY1109414T1 (el) Ν-σουλφονυλ πυρρολια και χρηση αυτων ως αναστολεις αποακετυλασης ιστονης
CY1115302T1 (el) Ενωση οξαζολιου και φαρμακευτικη συνθεση
CY1113450T1 (el) Διαμινοπυριμιδινες ως ρ2χ3 και ρ2χ2/3 ανταγωνιστες
EA200300595A1 (ru) Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора
PE20040636A1 (es) Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina
UY27918A1 (es) Derivados de benzodioxol
HRP20070510T3 (hr) Derivati benzimidazola i njihova upotreba kao antagonista ii receptora
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
CY1110863T1 (el) Παραγωγα του 2-(8,9-διοξο-2,6-διαζαδικυκλο (5.2.0)-εννε-1(7)-εν-2-υλ)αλκυλ-φωσφονικου οξεος και η χρηση τους ως ανταγωνιστων του ν-μεθυλ- d-ασπαρτικου (nmda) υποδοχεα
CY1112780T1 (el) Νεα σουλφονυλοπυρρολια ως αναστολεις της ηdac
GT200900187A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
PA8774201A1 (es) Antagonista del receptor
CO6190626A2 (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031216

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2197003B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20100312